Theseus Pharmaceuticals, Inc.
THRX · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.25 | -0.40 | 0.28 | -0.22 |
| FCF Yield | -9.40% | -2.46% | -4.95% | -5.16% |
| EV / EBITDA | -4.55 | -20.74 | -15.88 | -8.52 |
| Quality | ||||
| ROIC | -7.18% | -7.39% | -6.83% | -7.30% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.82 | 0.68 | 1.28 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -10.21% | 46.02% | -87.16% | -36.48% |
| Safety | ||||
| Net Debt / EBITDA | 2.64 | 2.49 | 6.21 | 7.56 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -9.02 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -5,250.37 | -1,369.49 | -1,267.46 | -2,944.54 |